Importantly, we confirmed these observations using a validation cohort of 60 endometrial cancers with well annotated clinical follow-up using quantitative PCR assays for ODC1. These data also indicated that endometrial cancers with elevated ODC1 had significantly shorter recurrence-free intervals (KM log-rank p = 0.0312, Wald test p = 5.59e-05) and an elevated hazard ratio 3.72 (Fig 2B). Here, ODC1 is linked to endometrial cancer.